Chudi Ndubaku, Montreal (CA); Jared Thomas Moore, San Rafael, CA (US); Paul Anthony Gibbons, San Francisco, CA (US); Jae Hyuk Chang, Alameda, CA (US); F. Anthony Romero, Redwood City, CA (US); Xiaohui Du, Belmont, CA (US); Hiroyuki Kawai, Pacifica, CA (US); Stephane Ciblat, Montreal (CA); Hong Wang, Montreal (CA); Vincent Albert, Montreal (CA); Lea Constantineau-Forget, Montreal (CA); Hugo De Almeida Silva, Montreal (CA); Dilan Emine Polat, Montreal (CA); Amit Nayyar, Montreal (CA); Daniel Gordon Michael Shore, San Mateo, CA (US); Kejia Wu, South San Francisco, CA (US); and Joanne Tan, San Mateo, CA (US)
Assigned to ORIC PHARMACEUTICALS, INC., South San Francisco, CA (US)
Filed by ORIC Pharmaceuticals, Inc., South San Francisco, CA (US)
Filed on Apr. 27, 2023, as Appl. No. 18/308,441.
Application 18/308,441 is a continuation of application No. PCT/US2022/028594, filed on May 10, 2022.
Claims priority of provisional application 63/337,445, filed on May 2, 2022.
Claims priority of provisional application 63/317,174, filed on Mar. 7, 2022.
Claims priority of provisional application 63/249,809, filed on Sep. 29, 2021.
Claims priority of provisional application 63/187,049, filed on May 11, 2021.
Prior Publication US 2023/0365537 A1, Nov. 16, 2023
